



1614
PATENT APPLICATION # 8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul A. RENHOWE, *et al.*

Date: February 26, 2002

Serial No.: 09/943,382

Docket No.: 072121:0139


Filed: August 30, 2001

Group Art Unit: 1614

For: **HETEROCYCLIC COMPOUNDS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on February 26, 2002.

Bernard P. Friedrichsen
(Name of applicant, assignee
or Registered Representative)


(Signature)

February 26, 2002
(Date of Signature)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Submitted herewith on Form PTO-1449 and presented below is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 C.F.R. §§1.97 and 1.98.

RECEIVED
MAR 06 2002
TECH CENTER 1600/2900

UNITED STATES PATENTS

<u>Inventor(s)</u>	<u>Patent No.</u>	<u>Date Issued</u>
Chen, et al.	5,073,492	Dec. 17, 1991
Bianco, et al.	5,585,380	Dec. 17, 1996
App, et al.	5,763,441	Jun. 9, 1998
App, et al.	5,792,771	Aug. 11, 1998
Okamoto, et al.	5,801,212	Sept. 1, 1998
Thorpe, et al.	5,855,866	Jan. 5, 1999
Hirth	5,942,385	Aug. 24, 1999
App, et al.	5,981,569	Nov. 9, 1999
Lohmann, et al.	6,258,951	Jul. 10, 2001

FOREIGN PATENTS

<u>Patent No.</u>	<u>Publication Date</u>	<u>Country</u>
✓ DE 23 63 459	June 26, 1975	Germany
✓ DE 198 41 985	March 9, 2000	Germany
✓ EP 0 747 771	Dec. 11, 1996	Europe
✓ EP 0 797 376	Sept. 24, 1997	Europe
✓ EP 1086705	Mar. 28, 2001	Europe
✓ JP 6-9952	Jan. 18, 1994	Japan
JP 7-43896	Feb. 14, 1995	Japan
✓ JP 8-29973	Feb. 2, 1996	Japan
✓ JP 63-258903	Oct. 26, 1988	Japan
WO 92/18483	Oct. 29, 1992	PCT
WO 97/34876	Sept. 25, 1997	PCT
WO 97/48694	Dec. 24, 1997	PCT
WO 98/13350	April 2, 1998	PCT
WO 99/10349	March 4, 1999	PCT
WO 99/65897	Dec. 23, 1999	PCT
WO 00/27379	May 18, 2000	PCT
WO 01/02369	Jan. 11, 2001	PCT
WO 01/28993	Apr. 26, 2001	PCT
WO 01/29025	Apr. 26, 2001	PCT
WO 01/52904	July 26, 2001	PCT
WO 01/55114	Aug. 2, 2001	PCT
WO 01/62251	Aug. 30, 2001	PCT
WO 01/62252	Aug. 30, 2001	PCT

OTHER DOCUMENTS

Matei, S., et al., "Condensation of ethyl 2-benzimidazoleacetate with carbonyl compounds," *Rev. Chim.*, Vol. 33, No. 6, pp. 527-530, 1989, published by the Central Institute of Chemistry, Bucharest, Romania.

Connolly, D., et al., "Human Vascular Permeability Factor," *J. Biol. Chem.*, Vol. 264, pp. 20017-20024, 1989, published by The American Society For Biochemistry and Molecular Biology, Inc., Stanford University Libraries' High Wire Press, California, United States of America.

Connolly, D., et al., "Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis," *J. Clin. Invest.*, Vol. 84, pp. 1470-1478, November 1989, published by The American Society for Clinical Investigation, Inc., Stanford University Libraries' High Wire Press, California, United States of America.

Leung, D., et al., "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen," *Science*, Vol. 246, pp. 1306-1309, December 8, 1989, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.

Plouet, J., et al., "Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells," *EMBO J.*, Vol. 8, No. 12, pp. 3801-3806, 1989, published by IRL Press.

Ullrich, A., et al., "Signal Transduction by Receptors with Tyrosine Kinase Activity," *Cell*, Vol. 61, pp. 203-212, April 20, 1990, published by Cell Press, Cambridge, Massachusetts, United States of America.

Shibuya, M., et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (*flt*) closely related to the *fms* family," *Oncogene*, Vol. 5, pp. 519-524, 1990, published by Macmillan Press Ltd., Stockton Press Company, Great Britain.

Terman, B., et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," *Oncogene*, Vol. 6, pp. 1677-1683, 1991, published by Macmillan Press Ltd., Stockton Press Company, Great Britain.

Aprelikova, O., et al., "*FLT4*, a novel Class III Receptor Tyrosine Kinase in chromosome 5q33-qter¹," *Cancer Res.*, Vol. 52, pp. 746-748, February 1, 1992, published by The American Association for Cancer Research, Stanford University Libraries' High Wire Press, California, United States of America.

DeVries, C., et al., "The *fms*-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," *Science*, Vol. 255, pp. 989-991, February 21, 1992, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.

Ukrainets, I., et al., "2-Carboethoxymethyl-4H-3,1-Benzoxazin-4-One. 3.*Condensation of o-Phenylenediamine," pp. 198-200, translated from *Khimiya Geterotsiklicheskikh Soedinii*, No. 2, pp. 239-241, February, 1992, published by Plenum Publ. Corp., London, Great Britain.

Ukrainets, I., et al., "4-Hydroxy-2-Quinolones 7.* Synthesis and Biological Properties of 1-R-3-(2-Benzimidazolyl)-4-Hydroxy-2-Quinolones," pp. 92-94, translated from *Khimiya Geterotsiklicheskikh Soedinii*, No. 1, pp. 105-108, January, 1993, published by Plenum Publ. Corp., London, Great Britain.

Quinn, T., et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," *Proc. Natl. Acad. Sci. USA*, Vol. 90, pp. 7533-7537, August, 1993.

Ukrainets, I., et al., "4-Hydroxy-2-Quinolones. 16.* Condensation of N-R-Substituted Amides of 2-Carboxy-Malonanilic Acid With o-Phenylenediamine," pp. 941-944, translated from *Khimiya Geterotsiklicheskikh Soedinii*, Vol. 8, pp. 1105-1108, August, 1993, published by Plenum Publ. Corp., London, Great Britain.

van der Geer, P., et al., "Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways," *Annu. Rev. Cell Biol.*, Vol. 10, pp. 251-337, 1994, published by Annual Reviews, Inc., Palo Alto, California, United States of America.

Mustonen, T., et al., "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis," *J. Cell Biology*, Vol. 129, No. 4, pp. 895-898, May, 1995, published by The Rockefeller University Press, New York, New York, United States of America.

Ukrainets, I., "Effective Synthesis of 3-(Benzimidazol-2-yl)-4-Hydroxy-2-Oxo-1,2-Dihydroquinolines," *Tet. Lett.*, Vol. 36, No. 42, pp. 7747-7748, 1995, published by Elsevier Science Ltd., Great Britain.

Folkman, J., "Fighting Cancer by Attacking Its Blood Supply," *Scientific American*, Vol. 275, pp. 150-154, September, 1996, published by Scientific American, Inc., New York, New York, United States of America.

Ukrainets, I., et al., "4-Hydroxy-2-Quinolones. 32.* Synthesis and Antithyroid Activity of Thio Analogs of 1H-2-OXO-3-(2-Benzimidazolyl)-4-HydroxyQuinoline," *Chem. Heterocyclic Comp.*, Vol. 33, No. 5, pp. 600-604, 1997, published by Kluwer Academic Publishers, London, Great Britain.

Ferrara, N., et al., "The Biology of Vascular Endothelial Growth Factor," *Endocrinol. Rev.*, Vol. 18, No. 1, pp. 4-25, 1997, published by The Endocrine Society, Stanford University Libraries' High Wire Press, California, United States of America.

Lymboussaki, A., "Vascular endothelial growth factors and their receptors in embryos, adults, and in tumors," Academic Dissertation, University of Helsinki, Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute, 1999.

REMARKS

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that this document is considered material to patentability as defined in 37

C.F.R. §1.56. Patentee does not waive any right to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present reexamination patent.

Applicants believe that this Information Disclosure Statement is being submitted prior to the mailing of an Office Action on the merits as set forth in 37 C.F.R. § 1.97(b)(3). Therefore, Applicants believe that no fee is due for this filing. In the event that an Office Action on the merits has been mailed, then Applicants submit this Information Disclosure Statement under 37 C.F.R. § 1.97(c)(2). Should any fee be due, the Patent Office is hereby authorized to charge any fees required for this filing to deposit account no. 06-1447. For the purpose of charging said deposit account, a duplicate of this document is submitted herewith.

It is requested that the foregoing documents be considered during examination of the accompanying application and be made of record therein.


Respectfully Submitted,

February 26, 2002

Date

Direct correspondence to:

David P. Lentini, Reg. No. 33,944
Attorney for Applicant
CHIRON CORPORATION
Intellectual Property - R440
P.O. Box 8097
Emeryville, California 94662-8097



Bernard P. Friedrichsen, Reg. No. 44,689
Foley & Lardner
150 East Gilman Street
P.O. Box 1497
Madison, Wisconsin 53701-1497
Tel: (608) 258-4281
Fax: (608) 258-4258